Overview In some hospitals, far too many people get a treatment they should not get, even when the evidence is clear that it is unnecessary or doesn’t work. Australia urgently needs a system to identify these outlier hospitals and make sure they are not putting patients at risk. To show how such a system could...

Overview: Poor implementation of a policy to get better value for PBS spending is costing government $320 million a year and raising questions about pharmaceutical industry involvement in drug pricing. The therapeutic group premium policy, introduced in 1998 to stop the government wasting money on over-priced drugs, has been so watered down that it is...

Enabling less highly-trained hospital workers to play a bigger role could improve jobs for doctors and nurses, save public hospitals nearly $430 million a year and fund treatment for more than 85,000 extra people, argues this report.

A better pricing system for public hospital treatment would show where costs are too high, and free up $1 billion for more and better health care, argues this report.

This report argues that Australia has a long way to go before consumers pay fair prices for pharmaceuticals. Overview Grattan Institute’s March 2013 report, Australia’s bad drug deal, showed that Australians paid more than $1 billion a year too much for prescription drugs. The problem is how the government sets prices. Vested interests are involved...